Literature DB >> 20535544

Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects.

María Cecilia Bottino1, Juan Pablo Cerliani, Paola Rojas, Sebastián Giulianelli, Rocío Soldati, Carolina Mondillo, María Alicia Gorostiaga, Omar P Pignataro, Juan Carlos Calvo, J Silvio Gutkind, Alfredo A Molinolo, Isabel A Lüthy, Claudia Lanari.   

Abstract

In this article, we demonstrate the expression of functional progesterone binding sites at the cell membrane in murine mammary carcinomas that are stimulated by progestins and inhibited by antiprogestins. Using confocal immunofluorescence, ligand binding and cell compartment-specific western blots, we were able to identify the presence of the classical progesterone receptors. Medroxyprogesterone acetate (MPA) and RU-486 (1 × 10(-11) and 1 × 10(-8) M) behaved as agonists activating extracellular signal-regulated kinases (ERKs) and progestin-regulated proteins, except for Cyclin D1 and Tissue factor which failed to increase with 1 × 10(-8) M RU-486, an experimental condition that allows PR to bind DNA. These results predicted a full agonist effect at low concentrations of RU-486. Accordingly, at concentrations lower than 1 × 10(-11) M, RU-486 increased cell proliferation in vitro. This effect was abolished by incubation with the ERK kinase inhibitor PD 98059 or by OH-tamoxifen. In vivo, at a daily dose of 1.2 μg/kg body weight RU-486 increased tumor growth, whereas at 12 mg/kg induces tumor regression. Our results indicate that low concentrations of MPA and RU-486 induce similar agonistic non-genomic effects, whereas RU-486 at higher concentrations may inhibit cell proliferation by genomic-induced effects. This suggests that RU-486 should be therapeutically administered at doses high enough to guarantee its genomic inhibitory effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535544     DOI: 10.1007/s10549-010-0971-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling.

Authors:  Chang Su; Rebecca L Cunningham; Nataliya Rybalchenko; Meharvan Singh
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

2.  Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury.

Authors:  Cindy K Barha; Tauheed Ishrat; Jonathan R Epp; Liisa A M Galea; Donald G Stein
Journal:  Exp Neurol       Date:  2011-06-13       Impact factor: 5.330

Review 3.  Physiological Action of Progesterone in the Nonhuman Primate Oviduct.

Authors:  Ov D Slayden; Fangzhou Luo; Cecily V Bishop
Journal:  Cells       Date:  2022-05-03       Impact factor: 7.666

Review 4.  Genomic and non-genomic effects of glucocorticoids: implications for breast cancer.

Authors:  Irma B Mitre-Aguilar; Alberto J Cabrera-Quintero; Alejandro Zentella-Dehesa
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Differential effects of synthetic progestagens on neuron survival and estrogen neuroprotection in cultured neurons.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Mol Cell Endocrinol       Date:  2014-01-11       Impact factor: 4.102

6.  Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.

Authors:  Benford Mafuvadze; Yayun Liang; Cynthia Besch-Williford; Xu Zhang; Salman M Hyder
Journal:  Horm Cancer       Date:  2012-05-09       Impact factor: 3.869

7.  The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Authors:  Ramiro Vázquez; María E Riveiro; Lucile Astorgues-Xerri; Elodie Odore; Keyvan Rezai; Eugenio Erba; Nicolò Panini; Andrea Rinaldi; Ivo Kwee; Luca Beltrame; Mohamed Bekradda; Esteban Cvitkovic; Francesco Bertoni; Roberta Frapolli; Maurizio D'Incalci
Journal:  Oncotarget       Date:  2017-01-31

8.  Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.

Authors:  Donata Ponikwicka-Tyszko; Marcin Chrusciel; Joanna Stelmaszewska; Piotr Bernaczyk; Paulina Chrusciel; Maria Sztachelska; Mika Scheinin; Mariusz Bidzinski; Jacek Szamatowicz; Ilpo T Huhtaniemi; Slawomir Wolczynski; Nafis A Rahman
Journal:  EBioMedicine       Date:  2019-08-26       Impact factor: 8.143

9.  Cortisol and Dexamethasone Mediate Glucocorticoid Actions in the Lesser Spotted Catshark (Scyliorhinus canicula).

Authors:  Juncal Cabrera-Busto; Juan M Mancera; Ignacio Ruiz-Jarabo
Journal:  Biology (Basel)       Date:  2021-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.